<DOC>
	<DOCNO>NCT01536873</DOCNO>
	<brief_summary>ING114916 open-label , multi-center , expanded access ( EAP ) study</brief_summary>
	<brief_title>Dolutegravir Expanded Access Study</brief_title>
	<detailed_description>ING114916 open-label , multi-center EAP allow access patient HIV-1 infection document raltegravir elvitegravir resistance , limited treatment option require dolutegravir construct viable anti-retroviral regimen therapy . Patients must eligible another ongoing dolutegravir clinical trial order participate EAP . The duration patient accrual study extend dolutegravir receives local ( country ) regulatory approval .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>1 . Adult subject great 18 year age 2 . Documented HIV1 RNA &gt; /= 400 c/mL 3 . Documented raltegravir elvitegravir resistance 4 . Inability construct viable background ART regimen commercially available medication . 1 . Creatnine clearance &lt; 30ml/min via CockcroftGault method 2 . Females pregnant and/or breastfeed 3 . Patients known integrase allergic reaction 4 . ALT &gt; 5 time ULN within one month treatment initiation 5 . ALT &gt; 3 time ULN total bilirubin &gt; 1.5 time ULN 6 . Evidence severe hepatic impairment 7 . Patients eligible , access , actively enrol DTG Phase III clinical study 8 . Any condition active clinically significant disease screening , anticipated requirement prohibit concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>treatment experience patient</keyword>
	<keyword>Integrase resistance</keyword>
</DOC>